Trial participant enrollment concluded for FAST-02, led by Varian.

The University of Cincinnati is at the forefront of a significant development in the field of radiotherapy treatment, with two of its esteemed doctors, John Perentesis, MD, and Emily Daugherty, MD, leading the charge in the FAST-02 clinical trial.

John Perentesis, MD, serves as the principal investigator for this trial, while Emily Daugherty, MD, takes on the role of co-lead investigator. Dr. Perentesis is also the director of the Cancer and Blood Disease Institute at Cincinnati Children's Hospital, and Dr. Daugherty is an associate professor of radiation oncology at the University of Cincinnati Cancer Center.

The FAST-02 trial is being conducted at the Cincinnati Children's Hospital/UC Health Proton Therapy Center in Ohio. This trial builds upon the findings from Siemens Healthineers' company Varian's FAST-01 trial, which focused on evaluating the clinical workflow feasibility of Flash therapy.

The FAST-02 trial targets thoracic bone metastases, a significant area of concern in cancer treatment. Specifically, the trial aims to treat symptomatic bone metastases in the thorax using Flash therapy, an investigational radiotherapy treatment.

The trial includes 10 patients and is being conducted at both Cincinnati Children's Hospital and the University of Cincinnati Cancer Center. Siemens Healthineers' company Varian has completed enrollment for the FAST-02 clinical trial.

The FAST-02 trial is a significant step toward bringing Flash radiotherapy treatment into clinical practice, according to the firm. The trial also evaluated treatment-related side effects for participants with bone metastases in the thorax, following on from the FAST-01 trial's focus on extremities.

At this time, there are no search results providing information about additional institutions involved in the FAST-02 clinical study project with John Perentesis and Emily Daugherty. The FAST-02 clinical trial is being led by these two investigators, marking a crucial moment in the advancement of radiotherapy treatment for thoracic bone metastases.